07:00 , Aug 4, 2016 |  BC Extra  |  Financial News

Ambrx raises $45M

Ambrx Inc. (San Diego, Calif.) said it raised $45 million in a financing round led by Apricot Capital and Northeast Securities Prosperity Healthcare Fund. Sinopharm Capital, Humanwell Healthcare Fund, Fosun Capital, Hopu Investments and the...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Clinical News

ARX788: Phase I started

Ambrx and Zhejiang began an open-label, Australian and New Zealand Phase I trial to evaluate 0.33, 0.66, 1.3, 2.2, 2.9 and 3.8 mg/kg IV ARX788 every 3 weeks in 80 patients. In 2013, Ambrx and...
01:00 , May 23, 2015 |  BC Extra  |  Company News

Chinese consortium to acquire Ambrx

A consortium consisting of Shanghai Fosun Pharmaceuticals Group Co. Ltd. (Shanghai:600196; HKSE:2196), WuXi PharmaTech Inc. (NYSE:WX), HOPU Investments and China Everbright Ltd.'s healthcare fund agreed to acquire Ambrx Inc. (La Jolla, Calif.) for an undisclosed...
07:00 , Aug 19, 2013 |  BioCentury  |  Product Development

The next wave in ADCs

After about 25 years of development, antibody-drug conjugates have gained acceptance as a validated approach to the targeted killing of cells, with two drugs approved in the past two years. While Seattle Genetics Inc. and...
07:00 , Jun 24, 2013 |  BC Week In Review  |  Company News

Ambrx, Zhejiang Medicine deal

Ambrx granted Zhejiang rights in China to develop and commercialize Ambrx's ARX788 to treat breast cancer. The antibody-drug conjugate (ADC) targets epidermal growth factor receptor 2 ( EGFR2; HER2; ErbB2; neu)...